Literature DB >> 2194426

Characterization of complement-fixing antibodies to peripheral nerve myelin in Guillain-Barré syndrome.

C L Koski1.   

Abstract

Complement-fixing antibodies to peripheral nerve myelin (anti-PNM Ab) can be detected in the serum of patients with Guillain-Barré syndrome (GBS). Kinetics of these antibodies can be correlated with the changing clinical course; the appearance of activation products of the terminal complement cascade in cerebrospinal fluid, serum, and peripheral nerve of patients with GBS; and the ability of GBS serum to mediate complement-dependent demyelination of myelinating cultures of rodent dorsal root ganglion. Some of the anti-PNM Ab in all GBS serum tested thus far bind a neutral glycolipid of human PNM and cross react with Forssman antigen, a cross-species antigen found in many infectious agents. Studies suggest that an IgM antibody in GBS patients that could be triggered by multiple infectious agents binds a surface determinant of a Forssman-like lipid of human PNM and participates in demyelination of peripheral nerve through the activation of complement.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194426     DOI: 10.1002/ana.410270712

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

Review 1.  Pathogenesis of neuroimmunologic diseases. Experimental models.

Authors:  C S Constantinescu; B Hilliard; T Fujioka; M K Bhopale; D Calida; A M Rostami
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

2.  Guillain-Barré syndrome following immunisation with Haemophilus influenzae type b conjugate vaccine.

Authors:  A Gervaix; M Caflisch; S Suter; C A Haenggeli
Journal:  Eur J Pediatr       Date:  1993-07       Impact factor: 3.183

3.  IgG monoclonal paraproteinaemia and peripheral neuropathy.

Authors:  A F Bleasel; S H Hawke; J D Pollard; J G McLeod
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

4.  High-dose intravenous immunoglobulin in the treatment of Guillain-Barré syndrome: a preliminary open study.

Authors:  M C Jackson; R B Godwin-Austen; A M Whiteley
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

5.  The membrane attack complex of complement mediates peripheral nervous system demyelination in vitro.

Authors:  W Brück; Y Brück; U Diederich; S J Piddlesden
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 6.  Guillain-Barré syndrome: clinical and immunological aspects.

Authors:  A M Rostami
Journal:  Springer Semin Immunopathol       Date:  1995

7.  Myelin- and microbe-specific antibodies in Guillain-Barré syndrome.

Authors:  J Terryberry; M Sutjita; Y Shoenfeld; B Gilburd; D Tanne; M Lorber; I Alosachie; N Barka; H C Lin; P Youinou
Journal:  J Clin Lab Anal       Date:  1995       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.